Asset profile
tradipitant · Vanda Pharmaceuticals (VNDA)
- Indication
- prevention of vomiting associated with GLP-1 receptor agonist therapy
- Also known as
- VP-VLY-686, NEREUS™
Company
VNDAVanda Pharmaceuticals
VNDAVanda PharmaceuticalsVanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the tre…
On the calendar
Timeline
Newest first.
Oct 27, 2026
06:50 PM
VNDAVanda PharmaceuticalsApr 8, 2026
08:44 PM
VNDAVanda PharmaceuticalsVanda initiates Thetis Phase 2 trial of tradipitant for GLP-1 vomiting
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT06138613 | Phase 3 | Active, not recruiting | Sep 30, 2027 | 705 | 1 of 1 sites in the United States |
| NCT02970968 | Phase 2 | Completed | Nov 1, 2018 | 152 | 38 of 38 sites in the United States |
| NCT02651714 | Phase 2 | Completed | Aug 4, 2017 | 168 | 28 of 28 sites in the United States |
| NCT06836557 | Phase 3 | Completed | Mar 30, 2026 | 17 | 0 of 3 sites in the United States |
| NCT05903924 | Phase 3 | Completed | Apr 6, 2024 | 316 | 5 of 5 sites in the United States |
| NCT03772340 | Phase 2 | Completed | Jun 6, 2019 | 126 | 1 of 1 sites in the United States |
| NCT06804603 | Phase 2 | Completed | Oct 6, 2025 | 124 | 3 of 3 sites in the United States |
| NCT03568331 | Phase 3 | Completed | Dec 27, 2019 | 375 | 70 of 70 sites in the United States |
| NCT04140695 | Phase 3 | Terminated | Oct 14, 2020 | 87 | 51 of 51 sites in the United States |
| NCT04327661 | Phase 3 | Completed | Apr 1, 2023 | 366 | 7 of 7 sites in the United States |
| NCT04326426 | Phase 3 | Enrolling by invitation | Aug 1, 2020 | 300 | 1 of 1 sites in the United States |
| NCT04028492 | Phase 3 | Completed | Feb 21, 2025 | 979 | 36 of 36 sites in the United States |
| NCT07446439 | Phase 3 | Recruiting | Dec 1, 2026 | 280 | 10 of 10 sites in the United States |
| NCT04849559 | Phase 1/2 | Completed | Sep 24, 2021 | 27 | 1 of 1 sites in the United States |
| NCT05653310 | Phase 2 | Enrolling by invitation | Mar 1, 2027 | 60 | 1 of 1 sites in the United States |
More from Vanda Pharmaceuticals
Other drugs and candidates from the same company tracked in this sector.